DAT-2000
/ Danatlas
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
Identification of DAT-2000A, a novel potent PARG inhibitor that selectively inhibits PARPi-resistant and homologous-recombination-deficient tumors
(AACR 2024)
- "Furthermore, it induces a dose and time-dependent accumulation of PAR chains, which may serve as a reliable pharmacodynamic biomarker indicative of PARG target engagement. In conclusion, DAT-2000A represents an innovative targeted therapy that warrants further investigation in clinical trials for the treatment of HRD cancers and beyond."
Breast Cancer • Oncology • Solid Tumor • HRD
1 to 1
Of
1
Go to page
1